Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 3/20 | 0.50 |
| ▸ | FNTB | P49356 | 3/20 | 0.50 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.50 |
| ▸ | HTR2A | P28223 | 12/20 | 0.42 |
| ▸ | HTR2C | P28335 | 12/20 | 0.42 |
| ▸ | HTR7 | P34969 | 12/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15124855 | 0.82 | FNTA (0.46) | FNTAFNTBPGGT1BHTR2AHTR2C | |
| SCHEMBL461297 | 0.77 | FNTA (0.58) | FNTAFNTBPGGT1BHTR2AHTR2C | |
| SCHEMBL15124423 | 0.76 | FNTA (0.44) | FNTAFNTBPGGT1BHTR2AHTR2C | |
| SCHEMBL15124470 | 0.75 | FNTA (0.59) | FNTAFNTBPGGT1B | |
| SCHEMBL462521 | 0.75 | FNTA (0.58) | FNTAFNTBPGGT1B | |
| SCHEMBL13560114 | 0.69 | PKM (0.61) | HTR2AHTR2CTSHRHPGD | |
| SCHEMBL29265678 | 0.67 | NPC1 (0.50) | TSHRHPGD | |
| SCHEMBL3482958 | 0.66 | PTGES (0.53) | HTR2AHTR2CHTR7PTGES | |
| SCHEMBL2865693 | 0.66 | KMT2A (0.46) | HTR2AHTR2CHTR7TSHR | |
| SCHEMBL8018027 | 0.66 | CYP2D6 (0.47) | HPGDRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040563-B2 | Dual inhibitors of farnesyltransferase and geranylgeranyltransferase I | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20130190355-A1 | DUAL INHIBITORS OF FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE I | YALE UNIVERSITY (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2012034038-A2 | DUAL INHIBITORS OF FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE I | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190355-A1 | DUAL INHIBITORS OF FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE I | FNTA, FNTB, GDI1 | FNTA 1/4885FNTB 2/4885PGGT1B 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.